Multiple Options, One Objective: Clearer Decisions in Resectable Non-Small Cell Lung Cancer. (PubMed, Cancers (Basel)) - Sep 27, 2026 - "Treatment of resectable NSCLC should be individualized based on stage, nodal status, PD-L1 expression, molecular alterations and pCR. Upfront surgery with adjuvant therapy is appropriate for lower-stage disease (IB-IIA), while perioperative chemoimmunotherapy offers maximal benefit in stage II-III, especially N2-positive patients. Biomarker-driven strategies will continue to refine patient selection to stop or continue postoperative treatment."
IO biomarker • Journal • Review • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • ALK • EGFR
|
|
Axelle Serena El Karak; Elio Nohra; Fadi El Karak; Ghadi Dagher; Tala Najdi
|